For the quarter ending 2026-03-31, LAB had $144,568K increase in cash & cash equivalents over the period. -$47,167K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 127,068 | 19,283 | -34,687 | -59,492 |
| Bargain purchase gain | - | 0 | 0 | 0 |
| Gain on sale of business | 172,289 | - | - | - |
| Stock-based compensation expense | 8,824 | 5,743 | 8,474 | 15,396 |
| Amortization of acquired intangible assets | 0 | 0 | 0 | 1,715 |
| Depreciation and amortization | 1,408 | 1,291 | 1,521 | 6,450 |
| Accretion of discount on short-term investments, net | 632 | 462 | 611 | 1,571 |
| Unrealized loss on equity investments | -3,494 | -602 | - | - |
| Non-cash lease expense | 1,355 | 1,584 | 1,570 | 2,865 |
| Provision for excess and obsolete inventory | 696 | 1,493 | 615 | 1,360 |
| Change in fair value of warrants | 0 | 0 | 0 | -232 |
| Change in fair value of contingent consideration | 0 | 223 | 0 | -3,400 |
| Other non-cash items | 67 | -17 | 445 | 477 |
| Accounts receivable, net | 1,858 | -6,730 | 5,794 | 2,297 |
| Inventory | -1,935 | 1,172 | 1,804 | 8,548 |
| Prepaid expenses and other assets | 1,592 | -3,023 | 705 | 1,175 |
| Deferred tax asset, non-current | 38,359 | -38,093 | - | - |
| Accounts payable | -1,224 | 653 | 946 | 838 |
| Accrued liabilities | -20,785 | 98 | 8,774 | 1,485 |
| Deferred revenue | -29,934 | -114 | 700 | -1,900 |
| Operating lease liabilities | -1,490 | -1,677 | -1,673 | -3,065 |
| Other liabilities | 1 | -378 | 27 | 143 |
| Net cash used in operating activities | -46,597 | -1,190 | -22,202 | -50,951 |
| Cash and restricted cash acquired in the merger | - | 0 | 0 | 0 |
| Acquisition of business, net of cash acquired | - | 0 | - | - |
| Cash received for sale of business, net | 363,222 | - | - | - |
| Purchases of short-term marketable debt securities | 127,208 | 99,110 | - | - |
| Purchases of long-term marketable debt securities | 58,517 | 32,321 | - | - |
| Purchases of short-term investments | - | - | 40,312 | 50,929 |
| Purchases of marketable equity securities | 837 | 6,857 | - | - |
| Purchases of long-term investments | - | - | 19,483 | - |
| Purchase of convertible note receivable | - | 5,000 | - | - |
| Proceeds from sales and maturities of investments | 15,000 | 25,000 | 54,000 | 100,000 |
| Purchases of property and equipment | 570 | 476 | 886 | 6,941 |
| Net cash provided by investing activities | 191,090 | -8,040 | -6,681 | 42,130 |
| Repayment of term loan and convertible notes | - | 0 | 0 | 0 |
| Payment of term loan fee | - | 0 | 0 | 0 |
| Repurchase of common stock | - | 0 | 0 | 0 |
| Proceeds from espp stock issuance | - | 215 | 0 | 308 |
| Payments for taxes related to net share settlement of equity awards and other | 118 | 126 | 112 | 246 |
| Proceeds from exercise of stock options | 78 | 531 | 0 | 0 |
| Net cash used in financing activities | -40 | 620 | -112 | 62 |
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | 115 | -100 | -203 | 1,145 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 144,568 | -8,710 | -29,198 | -7,614 |
| Cash, cash equivalents and restricted cash at beginning of period | 123,296 | 132,006 | 168,818 | - |
| Cash, cash equivalents and restricted cash at end of period | 267,864 | 123,296 | 132,006 | - |
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)